View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Dashboards
  2. Deals
July 12, 2022

Regenerative medicine deals dropped in the clinical trial operations in H1 2022

GlobalData's deals database looks at mergers, acquisitions and venture capital and private equity investments taking place worldwide.

By Data Journalism Team

In the first half of 2022 the number of deals relating to regenerative medicine decreased significantly by 43.2% from the same period in 2021.

This marks a deceleration in growth from the 25% decrease in deals that occurred in H2 2021 relative to the same period a year earlier.

GlobalData’s deals database looks at mergers, acquisitions and venture capital and private equity investments taking place daily between thousands of companies across the world.

During first half of 2022, deals relating to regenerative medicine accounted for 4.7% of all deals taking place in the sector. This represents a decrease from the figure of 6.9% in the first half of 2021.

GlobalData's thematic approach to sector activity seeks to group key company information on investments to see which industries are best placed to deal with any issues they may encounter.

These themes, of which regenerative medicine is one, are best thought of as "any issue that keeps a CEO awake at night", and by tracking them, it becomes possible to ascertain which companies are leading the way on specific issues and which ones have some work to do.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena